Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Document Type
Article
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abstract
Purpose: To provide evidence-based recommendations updating the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations.
Methods: ASCO updated recommendations on the basis of an ongoing systematic review of randomized control trials from 2020 to 2021.
Results: This guideline update reflects changes in evidence since the previous update. Two studies provide the evidence base. Outcomes of interest include efficacy and safety.
Recommendations: For patients with an anaplastic lymphoma kinase rearrangement, a performance status (PS) of 0-2, and previously untreated NSCLC, clinicians should offer alectinib or brigatinib or lorlatinib. For patients with an anaplastic lymphoma kinase rearrangement, a PS of 0-2, and previously untreated NSCLC, if alectinib, brigatinib, or lorlatinib are not available, clinicians should offer ceritinib or crizotinib. For patients with a RET rearrangement, a PS of 0-2, and previously untreated NSCLC, clinicians may offer selpercatinib or pralsetinib. In second line, for patients with a RET rearrangement who have not received RET-targeted therapy, clinicians may offer selpercatinib or pralsetinib.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
DOI
10.1200/JCO.22.00824
Publication Date
7-11-2022
Recommended Citation
Singh, Navneet; Temin, Sarah; Baker, Sherman Jr; Blanchard, Elizabeth; Brahmer, Julie R.; Celano, Paul; Duma, Narjust; Ellis, Peter M.; Elkins, Ivy B.; Haddad, Rami Y.; Hesketh, Paul J.; Jain, Dharamvir; Johnson, David H.; Leighl, Natasha B.; Mamdani, Hirva; Masters, Gregory; Moffitt, Pamela R.; Phillips, Tanyanika; Riely, Gregory J.; and Robinson, Andrew G., "Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline" (2022). Hematology-Oncology. 8.
https://scholarlycommons.gbmc.org/hem_onc/8
Comments
For full authors list please see citation or original publication.